APC and cancer: Conversely, targeting the upstream molecules of Wnt signaling, e.g., ligands and receptors, was initially considered ineffectual in cancer cells carrying mutations in Wnt signaling downstream (i.e., APC and β-catenin/CTNNB1) [93].